Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Farletuzumab - Eisai Inc

Next Previous
X
Search
Drug Profile

Farletuzumab - Eisai Inc

Alternative Names: Anti-GP-3 humanised mAb; Anti-GP3 humanised monoclonal antibody; MORAb-003

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ludwig Institute for Cancer Research; Morphotek
  • Developer Eisai Co Ltd; Eisai Inc; Morphotek
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Folate receptor 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours
  • Discontinued Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 20 Oct 2023 Pharmacodynamics data from a preclinical study in Endometrial cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 09 Jan 2023 Discontinued - Phase-II for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease) in Australia (IV)
  • 09 Jan 2023 Discontinued - Phase-II for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease) in Canada (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top